Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 27, 2009
Event: Termination of a Material Definitive Agreement and Asset Purchase.
On March 2, 2009, LeMaitre Vascular, Inc.'s wholly-owned subsidiary, Biomateriali S.r.l., entered into agreements with Edwards Lifesciences AG to terminate their existing Supply and Distribution Agreement and acquire related assets. The transaction officially closed on March 27, 2009.
Key Financial Metrics and Transaction Details
This filing details a specific transaction rather than periodic financial performance. The filing text does not provide clear values for overall company revenue, profit, cash flow, margins, debt, or liquidity.
| Transaction Component | Amount (EUR) | Amount (USD) |
|---|---|---|
| Early Termination Payment | 2,000,000 | 2,534,400 |
| Asset Purchase (Customer lists, contracts, inventory) | 625,000 | 792,000 |
| Total Cash Outflow | 2,625,000 | 3,326,400 |
Note: USD conversion based on the exchange rate of 1.2672 USD per Euro on March 2, 2009.
Material Changes Versus Prior Period
- Termination of Distribution Agreement: The exclusive distribution agreement for the AlboGraft Vascular Graft in Europe and certain international markets, originally set to run from January 1, 2009, to December 31, 2011, was terminated early.
- Asset Acquisition: Biomateriali acquired Edwards' AlboGraft inventory, customer lists, and assignable customer contracts.
- Operational Shift: Biomateriali will now manage sales and marketing directly, though Edwards will provide transition services and continue selling the product in certain markets for a service fee.
Guidance, Outlook, and Risks
Management Commentary: The transaction allows Biomateriali to take control of its distribution and marketing efforts for the AlboGraft Vascular Graft while securing existing inventory and customer relationships.
Transition Services: Edwards will provide sales and marketing cooperation and detailed customer information. Edwards will continue to sell the product in specific markets for the benefit of Biomateriali in exchange for a service fee.
Risks and Contingencies: The Termination Agreements include mutual indemnification provisions for losses arising from breaches or misrepresentations under the new agreements.
Important Facts for Investor Verification
- Verify the impact of the €2.625 million ($3.33 million) cash outflow on the company's current liquidity position.
- Confirm the specific terms of the "service fee" Edwards will charge for continued sales in certain markets.
- Assess the strategic rationale for terminating the exclusive distribution agreement less than three months after its commencement.
- Review the attached press release (Exhibit 99.1) for additional details on the transition timeline and market strategy.